Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030210007> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3030210007 endingPage "369" @default.
- W3030210007 startingPage "365" @default.
- W3030210007 abstract "ObjectiveTo investigate the clinical effect and the prospect of Infliximab in treatment of intravenous immunoglobulin(IVIG)-resistant Kawasaki disease(KD) patients.MethodsClinical features, inflammatory markers and coronary changes were observed in 2 cases of IVIG-resistant KD patients hospitalized in Peking University First Hospital, who were treated effectively by Infliximab.Relevant researches on the mechanism and progress of the Infliximab treatment for IVIG-resistant KD in the last 10 years were reviewed at the same time.ResultsTwo KD patients hospitalized in Peking University First Hospital had been treated with 2 g/kg IVIG for 2 times and followed by methylprednisolone treatment.However, fever and other clinical manifestations occurred again after 2 days and 6 days when temperature returned normal.They both defervesced and all the symptoms were improved after 1 dose of Infliximab(5 mg/kg) by laboratory examinations.Four published literatures of the basic research and 9 retrospective or prospective clinical researches of Infliximab treatment of KD showed that Infliximab alleviated the inflammatory level in the KD patients significantly.Complete remission was up to 72.73%-92.11%.Those KD patients defervesced within 12 h, with dramatic improvement of symptoms and signs.Arthralgia also disappeared in the patients with arthritis.Only 1 case was complicated with hepatitis in the acute phase and cholecystitis in recovery time.A phase 3 randomised, double-blinded, placebo-controlled trial had been done to assess the addition of Infliximab to the standard therapy.ConclusionsInfliximab is a feasible choice for IVIG-resistant KD patients.Efficacy and safety of Infliximab for KD treatment have been proved in the literature.However, Infliximab for KD treatment has not been indicated in the drug instruction, so the informed consent from the guardians and Ethics Committee is needed.Key words: Kawasaki disease; Intravenous immunoglobulin-resistance; Treatment; Infliximab; Tumor necrosis factor-α" @default.
- W3030210007 created "2020-06-05" @default.
- W3030210007 creator A5033746570 @default.
- W3030210007 creator A5043972628 @default.
- W3030210007 creator A5049949051 @default.
- W3030210007 creator A5051432360 @default.
- W3030210007 creator A5052437200 @default.
- W3030210007 creator A5080248487 @default.
- W3030210007 date "2015-03-05" @default.
- W3030210007 modified "2023-09-23" @default.
- W3030210007 title "Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease in 2 children and literature review" @default.
- W3030210007 doi "https://doi.org/10.3760/cma.j.issn.2095-428x.2015.05.014" @default.
- W3030210007 hasPublicationYear "2015" @default.
- W3030210007 type Work @default.
- W3030210007 sameAs 3030210007 @default.
- W3030210007 citedByCount "0" @default.
- W3030210007 crossrefType "journal-article" @default.
- W3030210007 hasAuthorship W3030210007A5033746570 @default.
- W3030210007 hasAuthorship W3030210007A5043972628 @default.
- W3030210007 hasAuthorship W3030210007A5049949051 @default.
- W3030210007 hasAuthorship W3030210007A5051432360 @default.
- W3030210007 hasAuthorship W3030210007A5052437200 @default.
- W3030210007 hasAuthorship W3030210007A5080248487 @default.
- W3030210007 hasConcept C126322002 @default.
- W3030210007 hasConcept C141071460 @default.
- W3030210007 hasConcept C142724271 @default.
- W3030210007 hasConcept C204787440 @default.
- W3030210007 hasConcept C27081682 @default.
- W3030210007 hasConcept C2776820930 @default.
- W3030210007 hasConcept C2777138892 @default.
- W3030210007 hasConcept C2779134260 @default.
- W3030210007 hasConcept C2780372218 @default.
- W3030210007 hasConcept C2781423770 @default.
- W3030210007 hasConcept C535046627 @default.
- W3030210007 hasConcept C71924100 @default.
- W3030210007 hasConcept C90924648 @default.
- W3030210007 hasConceptScore W3030210007C126322002 @default.
- W3030210007 hasConceptScore W3030210007C141071460 @default.
- W3030210007 hasConceptScore W3030210007C142724271 @default.
- W3030210007 hasConceptScore W3030210007C204787440 @default.
- W3030210007 hasConceptScore W3030210007C27081682 @default.
- W3030210007 hasConceptScore W3030210007C2776820930 @default.
- W3030210007 hasConceptScore W3030210007C2777138892 @default.
- W3030210007 hasConceptScore W3030210007C2779134260 @default.
- W3030210007 hasConceptScore W3030210007C2780372218 @default.
- W3030210007 hasConceptScore W3030210007C2781423770 @default.
- W3030210007 hasConceptScore W3030210007C535046627 @default.
- W3030210007 hasConceptScore W3030210007C71924100 @default.
- W3030210007 hasConceptScore W3030210007C90924648 @default.
- W3030210007 hasIssue "5" @default.
- W3030210007 hasLocation W30302100071 @default.
- W3030210007 hasOpenAccess W3030210007 @default.
- W3030210007 hasPrimaryLocation W30302100071 @default.
- W3030210007 hasRelatedWork W1515995290 @default.
- W3030210007 hasRelatedWork W1972195565 @default.
- W3030210007 hasRelatedWork W2004633631 @default.
- W3030210007 hasRelatedWork W2018010125 @default.
- W3030210007 hasRelatedWork W2080089273 @default.
- W3030210007 hasRelatedWork W2091638250 @default.
- W3030210007 hasRelatedWork W2112981410 @default.
- W3030210007 hasRelatedWork W2212818630 @default.
- W3030210007 hasRelatedWork W2240131929 @default.
- W3030210007 hasRelatedWork W2315308014 @default.
- W3030210007 hasRelatedWork W2319381636 @default.
- W3030210007 hasRelatedWork W2325954930 @default.
- W3030210007 hasRelatedWork W2401413971 @default.
- W3030210007 hasRelatedWork W2402146735 @default.
- W3030210007 hasRelatedWork W2744535196 @default.
- W3030210007 hasRelatedWork W2911552689 @default.
- W3030210007 hasRelatedWork W2942828317 @default.
- W3030210007 hasRelatedWork W2964677810 @default.
- W3030210007 hasRelatedWork W2979503914 @default.
- W3030210007 hasRelatedWork W3129735571 @default.
- W3030210007 hasVolume "30" @default.
- W3030210007 isParatext "false" @default.
- W3030210007 isRetracted "false" @default.
- W3030210007 magId "3030210007" @default.
- W3030210007 workType "article" @default.